Patents Assigned to Institute Pasteur
  • Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
    Patent number: 10767167
    Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: September 8, 2020
    Assignees: INSTITUT PASTEUR, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Pierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Sylvain Cardinaud, Christine Neuveut
  • Prevention and/or treatment of hearing loss or impairment
    Patent number: 10751385
    Abstract: The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AAV2/8 vector expressing at least one USH1 gene product, preferably SANS.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: August 25, 2020
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique (CNRS), Sorbonne Université, Université Clermont Auvergne
    Inventors: Christine Petit, Paul Avan, Sedigheh Delmaghani, Jean Defourny, Asadollah Aghaie, Saaid Safieddine, Alice Emptoz
  • Variants of terminal deoxynucleotidyl transferase and uses thereof
    Patent number: 10752887
    Abstract: The present invention relates to variants of Terminal deoxynucleotidyl Transferase (TdT), each of which (i) has an amino acid sequence similarity to SEQ ID NO: 2. 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33 or 35 with corresponding amino acid substitutions, (ii) is capable of synthesizing a nucleic acid fragment without a template and (iii) is capable of incorporating a modified nucleotide into the nucleic acid fragment.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: August 25, 2020
    Assignees: DNA Script, Institut Pasteur
    Inventors: Elise Champion, Mikhael Soskine, Thomas Ybert, Marc Delarue
  • Methods and pharmaceutical compositions for the treatment of bacterial superinfections post-influenza
    Patent number: 10736937
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of bacterial superinfections post-influenza. In particular, the present invention relates to a method of treating a bacterial superinfection post-influenza in a subject in need thereof comprising administering the subject with a therapeutically effective amount of a flagellin polypeptide optionally in combination with at least one antibiotic.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: August 11, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ DE LILLE, INSTITUT PASTEUR DE LILLE
    Inventors: Jean-Claude Sirard, Christophe Carnoy, François Trottein, Rémi Porte
  • METHOD, DEVICE, AND COMPUTER PROGRAM FOR IMPROVING THE RECONSTRUCTION OF DENSE SUPER-RESOLUTION IMAGES FROM DIFFRACTION-LIMITED IMAGES ACQUIRED BY SINGLE MOLECULE LOCALIZATION MICROSCOPY
    Publication number: 20200250794
    Abstract: The invention relates to reconstructing a synthetic dense super-resolution image from at least one low-information-content image, for example from a sequence of diffraction-limited images acquired by single molecule localization microscopy. After having obtained such a sequence of diffraction-limited images, a sparse localization image is reconstructed from the obtained sequence of diffraction-limited images according to single molecule localization microscopy image processing.
    Type: Application
    Filed: July 26, 2018
    Publication date: August 6, 2020
    Applicant: INSTITUT PASTEUR
    Inventors: Christophe ZIMMER, Wei OUYANG
  • OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
    Publication number: 20200248192
    Abstract: The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than (100), preferably no more than (10), restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.
    Type: Application
    Filed: February 2, 2018
    Publication date: August 6, 2020
    Applicants: Eligo Bioscience, Institut Pasteur
    Inventors: Antoine Decrulle, Jesus Fernandez Rodriguez, Xavier Duportet, David Bikard
  • Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
    Patent number: 10703801
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof that potently neutralize infection of both RABV and non-RABV lyssaviruses. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of RABV infection and infection with non-RABV lyssaviruses.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: July 7, 2020
    Assignees: HUMABS BIOMED SA, INSTITUT PASTEUR
    Inventors: Davide Corti, Hervé Bourhy
  • Mutant strains and methods of use
    Patent number: 10682377
    Abstract: A method of reducing or preventing the development of airway inflammation in a subject includes the step of infecting the respiratory tract of a subject an amount of a composition including a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria sufficient to colonize the respiratory tract of the subject. The step of infecting the subject with the live attenuated pertactin-deficient Bordetella bacteria results in reduction or prevention of the development of airway inflammation in the subject.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: June 16, 2020
    Assignees: Institut Pasteur de Lille, INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MÉDICALE
    Inventors: Luis Solans, Camille Locht, Anne Tsicopoulos, Saliha Ait-Yahia Sendid
  • Methods of Treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic Modulators
    Publication number: 20200155486
    Abstract: A method of treating obesity, preventing weight gain, reducing the rate of weight gain, and treating adverse effects related to obesity by administering SANA to induce thermogenesis in a subject.
    Type: Application
    Filed: September 20, 2019
    Publication date: May 21, 2020
    Applicants: Institut Pasteur de Montevideo, Universidad de la República
    Inventors: Carlos Batthyány, Gloria Virginia López, Carlos Escande, Jorge Rodriguez Duarte, Williams Arturo Porcal Quinta, Rosina Dapueto Capuccio, Germán Adrian Galliussi López, María Pia Garat Nuñez
  • Methods of Treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic Modulators
    Publication number: 20200147017
    Abstract: Methods of treating acute and chronic inflammatory conditions, tissue transplant rejection, and/or organ transplant rejection comprising administering to a subject in need thereof a therapeutically effective amount of a pluripotent anti-inflammatory and metabolic modulators optionally in combination with one or more secondary therapeutic agents and pharmaceutical compositions thereof.
    Type: Application
    Filed: January 17, 2020
    Publication date: May 14, 2020
    Applicants: Institut Pasteur de Montevideo, Universidad de la República
    Inventors: Carlos Batthyány, Gloria Virginia López, Carlos Escande, Jorge Rodriguez Duarte, Williams Arturo Porcal Quinta, Rosina Dapueto Capuccio, Germán Adrian Galliussi López, María Pia Garat Nuñez, Marcelo Hill, Mercedes Segovia
  • Nanobodies suitable for neuron regeneration therapy
    Patent number: 10640552
    Abstract: The invention is in the domain of delivery of molecules to brain cells across the blood-brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of such carrier, including a model for testing the capacity of such molecule to cross the blood-brain barrier and/or the toxicity of molecules on the blood brain barrier and/or the capacity of molecules that have crossed to target human brain cells (e.g. neurons, astrocytes and microglial cells).
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: May 5, 2020
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Christophe Prehaud, Monique Lafon, Pierre Lafaye
  • Monoclonal antibodies specific for serogroup X of and uses thereof in diagnosis
    Patent number: 10613085
    Abstract: The present invention is directed to monoclonal antibodies and antigen-binding portions thereof, specific for the capsular polysaccharides of Neisseria meningitidis serogroup X (NmX), wherein said antibodies or portions thereof are characterized by the sequences of the 6 CDR of the variable regions of the heavy and light chains. These antibodies are suitable for in vitro detection of Neisseria meningitidis serogroup X especially in a biological sample without purification of the capsular polysaccharides. The invention also concerns said monoclonal antibodiesor adequate portions thereofin different diagnostic tests and methods, in order to detect NmX. The invention discloses also a rapid diagnostic test for detecting NmX in a biological fluid.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: April 7, 2020
    Assignee: INSTITUT PASTEUR
    Inventors: Muhamed-Kheir Taha, Alain Agnememel
  • Lentiviral vector-based Japanese encephalitis immunogenic composition
    Patent number: 10603374
    Abstract: The present invention relates to a lentiviral vector-based Japanese encephalitis (JE) immunogenic composition. The present invention is directed to a recombinant lentiviral vector expressing the precursor of membrane (prM) and the envelope (E) protein, in particular glycoprotein of a Japanese encephalitis virus (JEV) or immunogenic fragments thereof. The present invention also provides cells expressing the lentiviral vector, uses and methods to prevent a JEV infection in a mammalian host, especially in a human or an animal host, in particular a pig or a piglet, preferably a domestic pig or a domestic piglet.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: March 31, 2020
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Pierre Charneau, Philippe Despres, Melissanne De Wispelaere, Philippe Souque, Marie-Pascale Frenkiel
  • RECOMBINANT MEASLES VIRUSES EXPRESSING EPITOPES OF ANTIGENS OF RNA VIRUSES - USE FOR THE PREPARATION OF VACCINE COMPOSITIONS
    Publication number: 20200095607
    Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
    Type: Application
    Filed: November 18, 2019
    Publication date: March 26, 2020
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Frederic TANGY, Clarisse LORIN, Lucile MOLLET, Frederic DELEBECQUE
  • In vitro blood-brain barrier model
    Patent number: 10591466
    Abstract: The invention is in the domain of delivery of molecules to brain cells across the blood-brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of such carrier, including a model for testing the capacity of such molecule to cross the blood-brain barrier and/or the toxicity of molecules on the blood brain barrier and/or the capacity of molecules that have crossed to target human brain cells (e/g. neurons, astrocytes and microglial cells).
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: March 17, 2020
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Christophe Prehaud, Monique Lafon, Pierre-Emmanuel Ceccaldi, Philippe Afonso, Pierre Lafaye
  • OB-fold used as scaffold for engineering new specific binders
    Patent number: 10584330
    Abstract: The present invention pertains to the field of protein engineering, and provides means for obtaining stable molecules that specifically bind to a target selected amongst a large variety of ligands families. In particular, the present invention provides methods for obtaining a molecule specifically binding to a target of interest, through a combinatorial mutation/selection approach with an OB-fold protein as a starting molecule. In particular, the target of interest can be of a different chemical nature form that of the native target of the OB-fold protein used as the starting molecule.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: March 10, 2020
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Frederic Pecorari, Pedro Alzari
  • Mitochondrial non-coding RNAs for predicting disease progression in heart failure and myocardial infarction patients
    Patent number: 10584383
    Abstract: The present invention relates to a method for predicting mortality of a test patient with chronic heart failure comprising based on detecting the expression level of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 8. The present invention also relates to a method for predicting cardiac remodeling after myocardial infarction in a test patient based on detecting the expression level of one or more lncRNAs selected from SEQ ID NOs 1 to 8.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: March 10, 2020
    Assignees: MEDIZINISCHE HOCHSCHULE HANNOVER, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITÉ DE LILLE 2 (LILLE 2)—UNIVERSITY OF LAW AND HEALTH, CENTRE HOSPITALIER UNIVERSITAIRE LILLE (CHU), INSTITUT PASTEUR DE LILLE (IPL)
    Inventors: Thomas Thum, Regalla Kumarswamy, Florence Pinet, Christophe Bauters, Pascal De Groote
  • OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
    Publication number: 20200040346
    Abstract: The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than 100, preferably no more than 10, restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.
    Type: Application
    Filed: July 31, 2019
    Publication date: February 6, 2020
    Applicants: Eligo Bioscience, Institut Pasteur
    Inventors: Antoine Decrulle, Jesus Fernandez Rodriguez, Xavier Duportet, David Bikard
  • Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
    Patent number: 10537537
    Abstract: Methods of treating acute and chronic inflammatory conditions, tissue transplant rejection, and/or organ transplant rejection comprising administering to a subject in need thereof a therapeutically effective amount of a pluripotent anti-inflammatory and metabolic modulators optionally in combination with one or more secondary therapeutic agents and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: January 21, 2020
    Assignees: Institut Pasteur de Montevideo, Universidad de la República
    Inventors: Carlos Batthyány, Gloria Virginia López, Carlos Escande, Jorge Rodriguez Duarte, Williams Arturo Porcal Quinta, Rosina Dapueto Capuccio, Germán Adrian Galliussi López, María Pia Garat Nuñez, Marcelo Hill, Mercedes Segovia
  • Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
    Patent number: 10538582
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: January 21, 2020
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger